EUROPEAN NEUROPSYCHOPHARMACOLOGY, published by Elsevier, is a prestigious academic journal that serves as a cornerstone in the field of neuropsychopharmacology, embracing multidisciplinary research at the intersection of neuroscience, psychiatry, and pharmacology. Since its establishment in 1990, this journal has consistently delivered cutting-edge research and reviews that drive forward our understanding of central nervous system disorders and their treatment. With an impressive impact factor and ranked in the Q1 category for several disciplines, including Biological Psychiatry and Neurology, it attracts submissions from leading researchers globally. The journal’s Scopus rankings reflect its significant influence, ranking in the top echelons across various categories such as Medicine and Neuroscience. While the journal maintains subscription access, readers are encouraged to explore the breadth of important findings that contribute to advancements in treatment options and improve patient care. EUROPEAN NEUROPSYCHOPHARMACOLOGY not only supports the dissemination of pivotal research but also fosters collaboration and dialogue within the scientific community, making it an essential resource for researchers, clinicians, and students dedicated to the complexities of brain health.

FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE is a pivotal journal in the fields of neurology, psychiatry, and related medical disciplines, published by GEORG THIEME VERLAG KG in Germany. With a history dating back to 1955, this journal has evolved to address the dynamic nature of neurological and psychiatric research, offering valuable insights and advancements in the field. Despite holding a Q4 category status in various medical domains according to the 2023 quartiles, the journal continues to foster academic discussion and engagement among researchers and clinicians alike. It serves as a vital platform for disseminating knowledge through original research articles, reviews, and clinical studies, making it an essential resource for professionals and students aiming to stay abreast of the latest developments in mental health and neurological science. Although the journal currently does not offer open access options, its contribution to the academic community is significant, helping to illuminate the intricate relationships between neurological disorders and psychiatric conditions.

NEUROSCIENCE LETTERS is a distinguished journal published by ELSEVIER IRELAND LTD, focusing on disseminating impactful research across the field of neuroscience. With its ISSN 0304-3940 and E-ISSN 1872-7972, the journal serves as a vital platform for researchers, professionals, and students aiming to explore the complexities of nervous system function and related disorders. Since its inception in 1975, NEUROSCIENCE LETTERS has contributed significantly to the field, currently positioned in the Q3 category for Miscellaneous Neuroscience, with a respectable Scopus rank of 52/113, placing it in the 54th percentile among its peers. The journal is published in Ireland and offers a comprehensive repository of scientific insights, methodologies, and innovative findings that advance our understanding of neurological phenomena. While not an open-access journal, it remains an essential resource for the latest advances in neuroscience research and the academic community’s collective knowledge.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a leading peer-reviewed journal that serves the interdisciplinary field of neuropsychopharmacology and biological psychiatry. With an impressive impact factor in the first quartile of both Biological Psychiatry and Pharmacology categories, this journal provides a critical platform for the dissemination of cutting-edge research and innovative therapeutic approaches. Covering a broad range of topics from the molecular mechanisms underlying psychiatric disorders to advanced pharmacological interventions, it aims to foster scientific dialogue among researchers, clinicians, and students alike. The journal has been at the forefront of scientific inquiry since its inception in 1982 and continues to evolve, adapting to the ever-changing landscape of neuroscience and mental health research. With its focus on high-quality articles and a commitment to advancing the understanding of neuropsychopharmacology, this journal is essential for anyone interested in the complexities of brain function and mental health.

EUROPEAN PSYCHIATRY, published by Cambridge University Press, stands at the forefront of advancements in the field of psychiatry and mental health, serving as a vital resource for researchers, professionals, and students alike. With an impressive Q1 ranking in Psychiatry and Mental Health and an impact factor that underscores its significance, this journal fosters innovative studies and discussions that shape contemporary understanding of mental health issues. Offering Open Access since 2020, it ensures that high-quality research is readily available to a global audience, bridging gaps in knowledge dissemination. The journal, which has been publishing since 1991, encompasses a broad range of topics relevant to mental health, emphasizing evidence-based practices and interdisciplinary approaches to treatment and care. With its ongoing commitment to excellence, EUROPEAN PSYCHIATRY continues to be an indispensable platform for advancing the science of mental health.

ASN Neuro is an esteemed academic journal published by Frontiers Media SA, focusing on critical advancements in the fields of neurology and neuroscience. Since its inception in 2009, it has established itself as an Open Access platform dedicated to fostering the dissemination of knowledge and research findings that address the complexities of the nervous system. With an impressive impact factor and consistently ranking in the top quartiles of its categories—Q1 in Neurology (clinical) and Q2 in Neuroscience (miscellaneous)—ASN Neuro is recognized for its high-quality publications that cater to the evolving challenges in clinical neurology and general neuroscience. Currently, it ranks 68th out of 400 journals in Clinical Neurology and 28th out of 113 in General Neuroscience, affirming its reputable position within the academic community. Researchers, professionals, and students alike are encouraged to contribute to and benefit from this impactful journal as it presents a unique opportunity to engage with cutting-edge research, innovative methodologies, and insightful reviews in the ever-evolving landscape of brain science.

The INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, published by OXFORD UNIV PRESS, is a leading open-access journal in the fields of pharmacology and psychiatry, with an impressive impact factor reflecting its prominence in academic research. Since its inception in 1998, the journal has provided a crucial platform for the publication of high-quality research, offering insights into the effects of neuropharmacological agents on mental health. As of 2023, it ranks in the Q1 category for both Pharmacology and Psychiatry & Mental Health, underscoring its relevance and authority within the scientific community. With notable rankings in various medical subspecialties, it attracts contributions that advance our understanding of psychiatric disorders and therapeutic strategies. The accessible nature of the journal, following its transition to open access in 2015, has expanded its reach, making knowledge and findings readily available to researchers, professionals, and students globally. This commitment to disseminating impactful research ensures the journal remains at the forefront of neuropsychopharmacological advancements.

NEUROSCIENCE RESEARCH, published by Elsevier Ireland Ltd, is a leading journal in the field of neuroscience, with a notable reputation for disseminating high-quality research that spans a variety of topics within the discipline. With an ISSN of 0168-0102 and an E-ISSN of 1872-8111, this journal serves as a vital platform for both established researchers and emerging voices in the field. Ranking in the Q2 quartile in both Medicine and Neuroscience categories, it has been recognized as a reliable source of innovative findings since its inception in 1984, with continuous publication through 2024. Although it does not currently offer Open Access options, the journal is indexed in Scopus, holding a significant position at Rank #48/113 in General Neuroscience, reflecting its contribution to advancing the understanding of neural mechanisms across various contexts. With its address anchored in Ireland, NEUROSCIENCE RESEARCH plays an essential role in bridging scientific inquiry and practical applications, making it an indispensable resource for researchers, professionals, and students dedicated to the burgeoning field of neuroscience.

Basic and Clinical Neuroscience, published by Iran University of Medical Sciences, is a distinguished open-access journal that has been operational since 2009, providing a platform for the dissemination of significant research in the fields of neuroscience and neurology. With the ISSN 2008-126X and E-ISSN 2228-7442, this journal serves as a vital resource for researchers, clinicians, and students by facilitating access to the latest findings and advancements in cellular and molecular neuroscience as well as clinical neurology. Although currently rated in Q4 for Cellular and Molecular Neuroscience and Q3 for Clinical Neurology as of 2023, it aims to enhance its standing through the publication of high-quality, peer-reviewed research. The journal has achieved a Scopus rank placing it in the 38th percentile for Neurology and the 13th percentile for Neuroscience, indicating a growing recognition of its contributions. With its commitment to open access, Basic and Clinical Neuroscience not only contributes to the scientific community in Iran but also strives to connect researchers worldwide, fostering collaborative efforts in tackling complex neurological challenges.

Progress in Neurology and Psychiatry is a pivotal journal published by John Wiley & Sons Ltd, dedicated to advancing the fields of neurology and psychiatry. With a robust history dating back to its establishment, this esteemed journal holds a consistent Q3 ranking in 2023 across several categories including Neurology, Clinical Neurology, Psychiatry, and Mental Health, signifying its significant contribution to the scientific community. This journal serves as a vital source of knowledge and insight, publishing original research, reviews, and case studies that explore the intricacies of neurological and psychiatric disorders. Although it does not offer open access, the journal remains accessible to a wide audience through institutional subscriptions. By fostering a platform for scholarly discourse, Progress in Neurology and Psychiatry aims to bridge the gap between research and practice, ultimately enhancing the quality of care for individuals with neurological and psychiatric conditions. Researchers, clinicians, and students are encouraged to engage with the journal's comprehensive content to stay informed of the latest developments and emerging trends in these critical fields of medicine.